Granisetron–dexamethasone combination reduces postoperative nausea and vomiting

Yoshitaka Fujii MD, Hiroyoshi Tanaka MD, Hidenori Toyooka MD*

The prophylactic antiemetic efficacy of combined granisetron and dexamethasone was evaluated in a randomized double-blind manner in 88 patients undergoing general anaesthesia for major gynaecological surgery. Immediately after recovery from anaesthesia, patients received a single dose of either placebo (saline, n = 22), granisetron (20 μg · kg^{-1}, n = 22), dexamethasone (8 mg, n = 22) or combined granisetron and dexamethasone (20 μg · kg^{-1} and 8 mg, respectively, n = 22) iv. The treatment groups were similar for patient demography, surgical procedures, anaesthetics administered and opioids given. Postoperatively, the frequency of nausea was 32%, 23%, 27% and 5% after administration of placebo, granisetron, dexamethasone and granisetron plus dexamethasone, respectively; the corresponding frequencies of vomiting were 23%, 23%, 23% and 5%. The incidence of adverse events postoperatively were not different among the groups. It is concluded that prophylactic administration of combined granisetron and dexamethasone is effective in preventing postoperative nausea and vomiting after anaesthesia.

L'efficacité prophylactique de l'association granisetron-dexaméthasone est évaluée dans une étude aléatoire à double insu chez 88 patientes soumises à une chirurgie gynécologique majeure sous anesthésie générale. Immédiatement après le réveil, les patientes reçoivent en dose unique, par la voie intraveineuse soit un placebo (sol. physiologique, n = 22), soit du granisetron (20 μg · kg^{-1}, n = 22), soit de la déxaméthasone (8 mg, n = 22) ou une association de granisetron et de déxaméthasone (20 μg · kg^{-1} et 8 mg respectivement, n = 22). Les groupes de traitement sont identiques sur le plan démographique, pour l'intervention chirurgicale, l'anesthésie et les morphiniques administrés. A la période postopératoire, la fréquence de la nausée est de 32%, 23%, 27% et 5% respectivement, après le placebo, le granisetron, la déxaméthasone et l'association granisetron-dexaméthasone: la fréquence correspondante pour les vomissements est de 23%, 23%, 23% et 5%. L'incidence des incidents postopératoires n'est pas différente entre les groupes. On conclut que l'administration de l'association granisetron-dexaméthasone est très efficace pour la prévention des nausées et vomissements postopératoires.

Key words
COMPLICATIONS: nausea, vomiting;
VOMITING: antiemetics, granisetron, dexamethasone, incidence, nausea;
SURGERY: gynaecological.

From the Department of Anaesthesiology, Toride Kyodo General Hospital, 5901-1, Terada, Toride City, Ibaraki 302, Japan, and *The Department of Anaesthesiology and Critical Care Medicine, Tokyo Medical and Dental University School of Medicine, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113, Japan.
Address correspondence to: Dr. Y. Fujii.
Accepted for publication 20th January, 1995.

Granisetron (Kytril®) is a 5-hydroxytryptamine (5-HT) antagonist with selectivity for 5-HT$_3$ receptors, and is effective in the treatment of emesis in patients receiving cisplatin chemotherapy.[1] Recent studies have evaluated the efficacy of granisetron in the reduction of postoperative nausea and vomiting,[2] and determined the appropriate dosage of granisetron for preventing postoperative emesis. Consequently, granisetron 40 μg · kg^{-1} was the optimal effective dose, and its antiemetic efficacy was superior to that of granisetron 20 μg · kg^{-1}.[3] It has been shown that dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen.[4] However, the combination of granisetron and dexamethasone for prophylaxis of postoperative emesis has not been reported. This study was designed to assess the efficacy of granisetron with dexamethasone in a randomized, double-blind comparison with granisetron or dexamethasone alone in patients undergoing major gynaecological surgery.

Methods

Eighty-eight female patients undergoing general anaesthesia for major gynaecological surgery were included in the study after approval by the institutional ethics com-

RETRACTED ARTICLE

TABLE I Patient demographies and types of operation

Group	*Placebo (n = 22)*	*Granisetron (n = 22)*	*Dexamethasone (n = 22)*	*Granisetron + dexamethasone (n = 22)*
Age (yr)	40.1 ± 7.5	45.3 ± 11.8	43.2 ± 8.3	42.5 ± 9.4
Height (cm)	154.0 ± 3.8	154.9 ± 4.8	156.3 ± 6.2	154.4 ± 4.9
Weight (kg)	54.0 ± 7.3	53.2 ± 8.0	54.9 ± 9.0	54.1 ± 7.6
Duration of operation (min)	74 ± 28	81 ± 24	78 ± 32	83 ± 25
Duration of anaesthesia (min)	96 ± 30	109 ± 26	103 ± 33	106 ± 25
Morphine administered (epidural) after operation (mg)	4.9 ± 0.8	4.9 ± 0.9	5.0 ± 0.9	5.0 ± 0.9
Types of operation performed				
- Abdominal hysterectomy	16	17	16	18
- Vaginal hysterectomy	0	1	0	0
- Salpingo-oophorectomy	4	3	5	2
- Others	2	1	1	2

All values are expressed as mean ± SD.

mittee, and informed consent was obtained. The patients were between 25 and 68 yr of age and ASA physical status I or II. No patient had cardiovascular, pulmonary, renal, hepatic or neurological diseases. No patient had received any antiemetic within 24 hr of surgery.

All patients received atropine sulphate 0.5 mg *im* 30 min before the induction of anaesthesia. In the operating room, the patients were placed in the lateral decubitus position. A 17-gauge Tuohy needle was inserted at the L_{2-3} or L_{3-4} interspace with a loss of resistance technique, and an 18-gauge epidural catheter was placed cephalad (approximately 5 cm) through the needle. Correct placement of the catheter was confirmed by administering a test dose of 2 ml lidocaine 1.5%. After catheter placement, the patients were placed in the supine position. Anaesthesia was induced with thiopentone 5 $mg \cdot kg^{-1}$ *iv* and succinylcholine 2 $mg \cdot kg^{-1}$ *iv* was used to facilitate tracheal intubation after precurarization with pancuronium 0.02 $mg \cdot kg^{-1}$ *iv*. After tracheal intubation, anaesthesia was maintained with nitrous oxide 4 $L \cdot min^{-1}$, oxygen 2 $L \cdot min^{-1}$ and isoflurane 0.5–2.0% (inspired concentration). Ventilation was controlled mechanically and was adjusted to maintain $P_{ET}CO_2$ between 35 and 40 mmHg with an anaesthetic/respiratory gas analyzer (Capnomac Ultima, Datex, Finland). After the circulation stabilized, 10-15 ml lidocaine 1.5% were injected through the epidural catheter. Muscle relaxants were used as required. At the end of surgery, atropine sulphate 0.02 $mg \cdot kg^{-1}$ and neostigmine 0.04 $mg \cdot kg^{-1}$ were administered *iv* for reversal of muscle relaxation, and the trachea was extubated. Rectal temperature was monitored and maintained at 37 ± 1°C. The patients received, in a randomized, double-blind manner, a single dose of placebo (saline), granisetron (20 $\mu g \cdot kg^{-1}$), dexamethasone (8 mg) or combined granisetron and dexamethasone (20 $\mu g \cdot kg^{-1}$ and 8 mg, respectively) *iv* immediately after emergence from anaesthesia. If two or more episodes of vomiting occurred for 24 hr after anaesthesia, standard antiemetic therapy (e.g., metoclopramide) was given. For postoperative analgesia, a continuous epidural infusion with a mixture with 40 ml bupivacaine 0.25% and morphine 0.1 $mg \cdot kg^{-1}$ was started after the completion of surgery at a rate of 1.7 $ml \cdot hr^{-1}$ (Drug infusion balloon catheter, Dib international, Japan). Postoperatively, patients in all groups received indomethacin (50 mg, *pr*) when they complained of pain.

Postoperatively, episodes of nausea and vomiting experienced by the patients were recorded during the first 24 hr after recovery from anaesthesia by direct questioning by anaesthetists who were blinded to which antiemetic the patient had received. Retching was not assessed as a separate entity, and the patients who experienced retching were classified as nauseous. The details of any side effect were also recorded throughout the study following either general questioning of the patients by anaesthetists or spontaneous comment by the patients.

Patients' demographic data were analyzed with one-way analysis of variance (ANOVA) and Student's t test. The frequency of postoperative emesis and the incidence of adverse events were compared with Wilcoxon signed-ranks test. A P value < 0.05 was considered significant. All values were expressed as mean ± SD.

Results

Patient demography and types of operation were not different among the groups (Table I).

During the 24 hr after recovery from anaesthesia, the frequencies of postoperative nausea and vomiting in patients who received granisetron plus dexamethasone were lower than those who had received placebo, granisetron

RETRACTED ARTICLE

TABLE II Number (percentage) of patients experienced nausea and vomiting during the 24 hr after anaesthesia

Group	*Placebo (n = 22)*	*Granisetron (n = 22)*	*Dexamethasone (n = 22)*	*Granisetron + dexamethasone (n = 22)*
No. (%) of patients experienced nausea	7 (32%)	5 (23%)	6 (27%)	1 (5%)
No. (%) of patients experienced vomiting	5 (23%)	5 (23%)	5 (23%)	1 (5%)

TABLE III Adverse events

Group	*Placebo (n = 22)*	*Granisetron (n = 22)*	*Dexamethasone (n = 22)*	*Granisetron + dexamethasone (n = 22)*
Any adverse events	5	4	5	4
- Headache	1	1	1	1
- Dizziness	2	1	2	1
- Drowsiness/sedation	1	1	0	1
- Others	1	1	2	1

or dexamethasone, respectively ($P < 0.05$) (Table II). No difference in the frequencies were observed among patients who received placebo, granisetron or dexamethasone. No additional antiemetics were administered in either group. The frequency of the use of indomethacin was approximately 5% in each group.

The most commonly reported complaints or adverse events in the four groups were headache, dizziness, drowsiness and sedation (Table III). There were no differences in the incidence of these events among groups.

Discussion

The major findings of the present study were that during the 24 hr after recovery from anaesthesia, the frequencies of postoperative nausea and vomiting in the combined granisetron and dexamethasone group were lower than that in placebo, granisetron or dexamethasone group ($P < 0.05$), while no differences were observed among the frequencies of the placebo, granisetron and dexamethasone groups.

Patients undergoing general anaesthesia for major gynaecological surgery have a high incidence of postoperative nausea and vomiting[5], which probably is of multifactorial origin.[6] A number of factors including age, obesity, surgical procedure, type of anaesthesia and postoperative pain are considered to increase the incidence of these postoperative symptoms. In the present study, however, the treatment groups were similar for patient demography, types of operation, anaesthetic administered and morphine dose used postoperatively. Therefore, the differences in the frequencies among the groups can be attributed to the difference in the agents administered.

Granisetron has already been proved to be effective in the prevention of nausea and vomiting induced by cancer chemotherapy.[1] Our recent studies have also demonstrated that granisetron has a potent antiemetic effect in postoperative emesis, and have shown that the antiemetic efficacy of granisetron 40 $\mu g \cdot kg^{-1}$ is superior to that of granisetron 20 $\mu g \cdot kg^{-1}$.[2,3] The results of the present study, with administration of placebo or granisetron 20 $\mu g \cdot kg^{-1}$, showed that no difference in the efficacy between the two groups for preventing postoperative nausea and vomiting. These were in agreement with our previous study.[3]

It has been reported that dexamethasone (8 mg) decreases chemotherapy-induced emesis when added to a standard antiemetic regimen.[4] In the present study, therefore, the same dose of dexamethasone was added to granisetron.

The present study also demonstrated that frequencies of nausea and vomiting in patients who had received granisetron 20 $\mu g \cdot kg^{-1}$ plus dexamethasone 8 mg were lower than those in patients who had received granisetron 20 $\mu g \cdot kg^{-1}$ or dexamethasone 8 mg alone during the 24 hr after recovery from anaesthesia. Furthermore, the frequencies in patients who had received the combination of granisetron 20 $\mu g \cdot kg^{-1}$ and dexamethasone 8 mg were almost the same as those in patients who had received granisetron 40 $\mu g \cdot kg^{-1}$ in our previous study.[3] This suggests that the combination of granisetron and dexameth-

RETRACTED ARTICLE

asone is more effective in the prevention of postoperative nausea and vomiting after anaesthesia, and that its effect is almost equal to that of granisetron 40 $\mu g \cdot kg^{-1}$ (i.e., optimal antiemetic dose). In the present study, however, comparison of granisetron 40 $\mu g \cdot kg^{-1}$ with granisetron plus dexamethasone in the prevention of postoperative emeis was not performed. Therefore, further studies are needed.

Although the exact mechanism of the combination of granisetron and dexamethasone in preventing postoperative emesis is not known, it has been suggested that granisetron (>40 $\mu g \cdot kg^{-1}$) may act on the sites containing a number of 5-HT_3 receptors with demonstrated antiemetic effects,[3,7] and that high-dose dexamethasone (>10 mg) may inhibit the synthesis of prostaglandin which is related to the trigger of emesis.[8] In the present study, the reduction of postoperative nausea and vomiting with either granisetron 20 $\mu g \cdot kg^{-1}$ or dexamethasone 8 mg alone was not observed. However, administration of combined granisetron and dexamethasone (20 $\mu g \cdot kg^{-1}$ and 8 mg, respectively) reduced the incidence of postoperative emesis. Therefore, it is possible that the combination of both agents enhances each antiemetic effectiveness during the 24 hr after anaesthesia.

The side effects observed in the present study were relatively mild, and there were no differences in the incidence of adverse events among the groups. Therefore, it does not appear that granisetron with dexamethasone affects mental status to produce headache, dizziness, drowsiness or sedation.

Our hospital pharmacy pays 10,020 ¥ for granisetron 3 mg (approximately 60 $\mu g \cdot kg^{-1}$) and 536 ¥ for dexamethasone 8 mg. Therefore, the smaller dose of granisetron (i.e., 20 $\mu g \cdot kg^{-1}$) plus dexamethasone would decrease the cost preventing nausea and vomiting.

In conclusion, an administration of granisetron 20 $\mu g \cdot kg^{-1}$ plus dexamethasone 8 mg *iv* is more effective in the prophylaxis of postoperative nausea and vomiting after recovery from anaesthesia than that of granisetron 20 $\mu g \cdot kg^{-1}$ alone, and has few adverse events.

References

1 *Bermudez J, Boyle EA, Minter WD, Sanger GJ.* The antiemetic potential of the 5-hydroxytryptamine$_3$ receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.

2 *Fujii Y, Tanaka H, Toyooka H.* Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41: 291–4.

3 *Fujii Y, Tanaka H, Toyooka H.* Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth 1994; 41: 794–7.

4 *Smith DB, Newlands ES, Rustin GJS, et al.* Comparison of ondanestron and ondanestron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487–90.

5 *McKenzie R, Wadhwa RK, Uy NTL, et al.* Antiemetic effectiveness of intramuscular hydroxyzine compared with intramuscular droperidol. Anesth Analg 1981; 60: 783–8.

6 *Watcha MF, White PF.* Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.

7 *Carmichael J, Cantwell BMJ, Edwards CM, et al.* A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT_3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.

8 *Aapro MS, Plezia PM, Alberts DS, et al.* Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984; 2: 466–71.

RETRACTED ARTICLE